JP2016516751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516751A5 JP2016516751A5 JP2016506282A JP2016506282A JP2016516751A5 JP 2016516751 A5 JP2016516751 A5 JP 2016516751A5 JP 2016506282 A JP2016506282 A JP 2016506282A JP 2016506282 A JP2016506282 A JP 2016506282A JP 2016516751 A5 JP2016516751 A5 JP 2016516751A5
- Authority
- JP
- Japan
- Prior art keywords
- propolis
- composition
- weight
- cyclodextrin
- gastrointestinal cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000241413 Propolis Species 0.000 claims description 84
- 229940069949 propolis Drugs 0.000 claims description 84
- 239000000203 mixture Substances 0.000 claims description 73
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 44
- 229920000858 Cyclodextrin Polymers 0.000 claims description 32
- 239000011347 resin Substances 0.000 claims description 22
- 229920005989 resin Polymers 0.000 claims description 22
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 21
- RTIXKCRFFJGDFG-UHFFFAOYSA-N Chrysin Natural products C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 claims description 20
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 16
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 claims description 14
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 10
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 9
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 8
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 claims description 8
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 claims description 7
- 229940043370 chrysin Drugs 0.000 claims description 7
- 235000015838 chrysin Nutrition 0.000 claims description 7
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 claims description 7
- FGUBFGWYEYFGRK-HNNXBMFYSA-N Pinocembrin Natural products Cc1cc(C)c2C(=O)C[C@H](Oc2c1)c3ccccc3 FGUBFGWYEYFGRK-HNNXBMFYSA-N 0.000 claims description 6
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 6
- URFCJEUYXNAHFI-ZDUSSCGKSA-N pinocembrin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=CC=C1 URFCJEUYXNAHFI-ZDUSSCGKSA-N 0.000 claims description 6
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 5
- 229940074360 caffeic acid Drugs 0.000 claims description 5
- 235000004883 caffeic acid Nutrition 0.000 claims description 5
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- LDBPIZIYTBIRPM-VQHVLOKHSA-N phenyl (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OC1=CC=CC=C1 LDBPIZIYTBIRPM-VQHVLOKHSA-N 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 210000005170 neoplastic cell Anatomy 0.000 claims description 4
- 230000001613 neoplastic effect Effects 0.000 claims description 4
- 230000004043 responsiveness Effects 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 230000005740 tumor formation Effects 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 241000219000 Populus Species 0.000 claims description 2
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- SUYJZKRQHBQNCA-LSDHHAIUSA-N pinobanksin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=CC=C1 SUYJZKRQHBQNCA-LSDHHAIUSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- 230000002401 inhibitory effect Effects 0.000 description 3
- WWVKQTNONPWVEL-VQHVLOKHSA-N benzyl (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-VQHVLOKHSA-N 0.000 description 2
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ60907413 | 2013-04-05 | ||
| NZ609074 | 2013-04-05 | ||
| PCT/NZ2014/000060 WO2014163513A1 (en) | 2013-04-05 | 2014-04-07 | Therapeutic compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516751A JP2016516751A (ja) | 2016-06-09 |
| JP2016516751A5 true JP2016516751A5 (enExample) | 2017-08-03 |
| JP6429859B2 JP6429859B2 (ja) | 2018-11-28 |
Family
ID=51658696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506282A Active JP6429859B2 (ja) | 2013-04-05 | 2014-04-07 | 治療用組成物およびその用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160051594A1 (enExample) |
| EP (1) | EP2983681B1 (enExample) |
| JP (1) | JP6429859B2 (enExample) |
| KR (1) | KR20160021081A (enExample) |
| CN (1) | CN105307665B (enExample) |
| AU (1) | AU2014250139B2 (enExample) |
| BR (1) | BR112015025025A2 (enExample) |
| CA (1) | CA2908185A1 (enExample) |
| EA (1) | EA201591925A1 (enExample) |
| SG (1) | SG11201508167PA (enExample) |
| TW (1) | TW201532608A (enExample) |
| WO (1) | WO2014163513A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105163728B (zh) * | 2013-04-05 | 2018-10-02 | 蜜纽康新西兰有限公司 | 包含蜂胶提取物的治疗性组合物和其用途 |
| EP2983681B1 (en) * | 2013-04-05 | 2020-07-15 | Manuka Health New Zealand Limited | Therapeutic compositions and uses thereof |
| TW201609113A (zh) * | 2014-07-18 | 2016-03-16 | 歐文 約翰 蓋奇波 | 治療組合物及其用途 |
| JP2019515943A (ja) * | 2016-03-24 | 2019-06-13 | マヌカ ヘルス ニュージーランド リミテッド | 治療用組成物およびその使用 |
| ITUA20163755A1 (it) * | 2016-05-24 | 2017-11-24 | Aboca Spa Societa Agricola | Composizioni a base di gemme di pioppo e loro usi |
| CN107194205B (zh) * | 2017-05-31 | 2020-11-24 | 浙江大学 | 具有杀菌活性的jak2激酶抑制剂及其虚拟筛选方法 |
| WO2019226469A1 (en) * | 2018-05-19 | 2019-11-28 | Fort Lewis College | Chemical compositions for combating honey bee pests and pathogens |
| RU2697839C1 (ru) * | 2018-11-14 | 2019-08-21 | Александр Александрович Кролевец | Способ получения нанокапсул сухого экстракта прополиса |
| JP7166965B2 (ja) * | 2019-03-13 | 2022-11-08 | 株式会社ファンケル | ｂＦＧＦ発現増強用組成物 |
| TR201908777A2 (tr) * | 2019-06-13 | 2019-07-22 | Sbs Bilimsel Bio Coezuemler Sanayi Ve Ticaret A S | Suda Çözünür ve Suda Çözünür Olmayan Özellikte Yüksek Antioksidan Kapasitesine Sahip Propolis Ürünleri ve Üretim Yöntemi |
| CA3171585A1 (en) * | 2020-03-13 | 2021-09-16 | Alli Murugesan | Composition and use of a caffeic acid phenethyl ester (cape) compound to treat cancer |
| KR102470869B1 (ko) * | 2020-12-18 | 2022-11-29 | 대한민국 | 프로테아좀 저해제 및 프로폴리스를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 및 이의 용도 |
| CN117551222A (zh) * | 2022-08-04 | 2024-02-13 | 中科中山药物创新研究院 | 大蒜素-环糊精包合物共晶的晶型及其制备方法和应用 |
| CN116492324A (zh) * | 2023-01-04 | 2023-07-28 | 河南科技大学第一附属医院 | 咖啡酸在预防和治疗结直肠癌中的应用、含咖啡酸的药物 |
| WO2024246220A1 (en) * | 2023-05-31 | 2024-12-05 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating lung cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JP3035834B2 (ja) * | 1991-04-11 | 2000-04-24 | 株式会社林原生物化学研究所 | プロポリス成分含有固状物とその製造方法並びに用途 |
| US5561116A (en) * | 1991-04-11 | 1996-10-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Solid product containing propolis components, and preparation and uses thereof |
| US5922324A (en) | 1995-01-31 | 1999-07-13 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Propolis extract with improved water-solubility |
| JP4135816B2 (ja) * | 1995-11-24 | 2008-08-20 | 株式会社林原生物化学研究所 | 水溶性を向上させたプロポリス抽出物 |
| CN1241577C (zh) * | 2003-03-13 | 2006-02-15 | 吉林大学 | 环糊精衍生物的药物用途及其药物组合物 |
| JP4950682B2 (ja) * | 2007-01-30 | 2012-06-13 | アピ株式会社 | プロポリス抽出物 |
| GR1007520B (el) * | 2010-12-02 | 2012-02-02 | Apivita - Καλλυντικα - Διαιτητικα - Φαρμακα Ανωνυμη Εμπορικη Και Βιοτεχνικη Εταιρεια, | Ταυτοχρονη εκχυλιση και σχηματισμος συμπλοκων εγκλεισμου των δραστικων συστατικων της προπολης με υδροξυπροπυλο-β-κυκλοδεξτρινη |
| US20130309218A1 (en) * | 2011-01-31 | 2013-11-21 | Wacker Chemie Ag | Process for producing aqueous solution containing fat-soluble substance |
| EP2983681B1 (en) * | 2013-04-05 | 2020-07-15 | Manuka Health New Zealand Limited | Therapeutic compositions and uses thereof |
| CN105163728B (zh) | 2013-04-05 | 2018-10-02 | 蜜纽康新西兰有限公司 | 包含蜂胶提取物的治疗性组合物和其用途 |
-
2014
- 2014-04-07 EP EP14779790.6A patent/EP2983681B1/en active Active
- 2014-04-07 JP JP2016506282A patent/JP6429859B2/ja active Active
- 2014-04-07 CN CN201480030083.7A patent/CN105307665B/zh active Active
- 2014-04-07 CA CA2908185A patent/CA2908185A1/en not_active Abandoned
- 2014-04-07 KR KR1020157030505A patent/KR20160021081A/ko not_active Withdrawn
- 2014-04-07 AU AU2014250139A patent/AU2014250139B2/en active Active
- 2014-04-07 WO PCT/NZ2014/000060 patent/WO2014163513A1/en not_active Ceased
- 2014-04-07 US US14/781,863 patent/US20160051594A1/en not_active Abandoned
- 2014-04-07 TW TW103112676A patent/TW201532608A/zh unknown
- 2014-04-07 EA EA201591925A patent/EA201591925A1/ru unknown
- 2014-04-07 BR BR112015025025A patent/BR112015025025A2/pt not_active IP Right Cessation
- 2014-04-07 SG SG11201508167PA patent/SG11201508167PA/en unknown
-
2017
- 2017-03-21 US US15/465,414 patent/US10420804B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516751A5 (enExample) | ||
| Peng et al. | Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice | |
| LS | Propolis in dentistry and oral cancer management | |
| JP2016515615A5 (enExample) | ||
| Yang et al. | mTOR-mediated immunometabolic reprogramming nanomodulators enable sensitive switching of energy deprivation-induced microglial polarization for Alzheimer’s disease management | |
| Timmer et al. | Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels | |
| JP2016519107A5 (enExample) | ||
| JP2016535780A5 (enExample) | ||
| RaviKKumar et al. | A comprehensive review on ulcer and their treatment | |
| JP2014525454A5 (enExample) | ||
| Hu et al. | Tetramethylpyrazine facilitates functional recovery after spinal cord injury by inhibiting MMP2, MMP9, and vascular endothelial cell apoptosis | |
| Basu et al. | Toxicity with radiotherapy for oral cancers and its management: A practical approach | |
| JP2016535044A5 (enExample) | ||
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| PH12017500646A1 (en) | Treatment or prevention of anaemia in pregnant non-human mammals | |
| JP2016069317A5 (ja) | 腎不全進行抑制剤、腎不全予防剤、尿毒症治療剤、インドキシル硫酸産生阻害剤、心血管系疾患予防剤、及び食品組成物 | |
| JP2015513554A5 (enExample) | ||
| Wu et al. | Protective effect of interleukin-10 and recombinant human keratinocyte growth factor-2 on ventilation-induced lung injury in rats | |
| Taddio et al. | From skin to gut | |
| Li et al. | DIPG-89. ENHANCEMENT OF BLOOD-BRAIN BARRIER PENETRATION AND TUMOR TARGETED DRUG DELIVERY FOR DMG USING A P-SELECTIN TARGETED NANOMEDICINE APPROACH | |
| Urasinski et al. | Prophylaxis with a recombinant factor IX (BAX326*) in pediatric PTPS with hemophilia B: PO087 | |
| Frazilio et al. | Evaluation of neuronal apoptosis precursors in an experimental model of acute normovolemic hemodilution | |
| Eckenhoff et al. | A Smoking Gun but Still No Victim | |
| CN106913873A (zh) | 巴西绿蜂胶在制备pdt抗肿瘤的协同增效药物中的应用 | |
| Jackson et al. | DIPG-88. TARGETING THE ANTIOXIDANT RESPONSE ELEMENT AXIS SENSITIZES DIFFUSE MIDLINE GLIOMA CELLS TO ONC201 |